• Explore /
  • Poster
  • / Phase I study of a new concept cancer vaccine composed artificial intelligence (AI)-designed shared-antigen peptides plus combined synergistically activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCENT 1).

Phase I study of a new concept cancer vaccine composed artificial intelligence (AI)-designed shared-antigen peptides plus combined synergistically activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCENT 1).

Abstract Poster

Authors

Sadahisa Ogasawara

Sadahisa Ogasawara

Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan

Sadahisa Ogasawara , Hiroaki Kanzaki , Keisuke Koroki , Kengo Kanayama , Susumu Maruta , Kazufumi Kobayashi , Souichiro Kiyono , Masato Nakamura , Naoya Kanogawa , Takayuki Kondo , Eiichiro Suzuki , Yoshihiko Ooka , Shingo Nakamoto , Akinobu Tawada , Tetsuhiro Chiba , Makoto Arai , Hiroyuki Nakada , Nobuko Yamaguchi , Hideki Hanaoka , Naoya Kato

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

jRCT2031190072

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS595)

Abstract #

TPS595

Poster Bd #

P8

Abstract Disclosures

Similar Posters

First Author: Masafumi Ikeda

Poster

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

First-in-human study of the cancer peptide vaccine, TAS0313, in patients with advanced solid tumors: Phase I dose-finding part results.

First-in-human study of the cancer peptide vaccine, TAS0313, in patients with advanced solid tumors: Phase I dose-finding part results.

First Author: Noboru Yamamoto

First Author: Hiroto Matsui

Poster

2023 ASCO Gastrointestinal Cancers Symposium

A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).

A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).

First Author: Changqing Xie